143 related articles for article (PubMed ID: 22143340)
21. Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors.
Exarchou SA; Voulgari PV; Markatseli TE; Zioga A; Drosos AA
Scand J Rheumatol; 2009; 38(5):328-31. PubMed ID: 19579151
[TBL] [Abstract][Full Text] [Related]
22. Abdominal aortitis in HLA-B27+ spondyloarthritis: case report with 5-year follow-up and literature review.
Grewal GS; Leipsic J; Klinkhoff AV
Semin Arthritis Rheum; 2014 Dec; 44(3):305-8. PubMed ID: 24935530
[TBL] [Abstract][Full Text] [Related]
23. Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period.
Conti F; Ceccarelli F; Marocchi E; Magrini L; Spinelli FR; Spadaro A; Scrivo R; Valesini G
Ann Rheum Dis; 2007 Oct; 66(10):1393-7. PubMed ID: 17613555
[TBL] [Abstract][Full Text] [Related]
24. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study.
Fagerli KM; Lie E; van der Heijde D; Heiberg MS; Lexberg AS; Rødevand E; Kalstad S; Mikkelsen K; Kvien TK
Ann Rheum Dis; 2014 Jan; 73(1):132-7. PubMed ID: 23291385
[TBL] [Abstract][Full Text] [Related]
25. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept.
Lee JH; Slifman NR; Gershon SK; Edwards ET; Schwieterman WD; Siegel JN; Wise RP; Brown SL; Udall JN; Braun MM
Arthritis Rheum; 2002 Oct; 46(10):2565-70. PubMed ID: 12384912
[TBL] [Abstract][Full Text] [Related]
26. Guideline for anti-TNF-alpha therapy in psoriatic arthritis.
Kyle S; Chandler D; Griffiths CE; Helliwell P; Lewis J; McInnes I; Oliver S; Symmons D; McHugh N;
Rheumatology (Oxford); 2005 Mar; 44(3):390-7. PubMed ID: 15695305
[No Abstract] [Full Text] [Related]
27. Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study.
Saougou I; Markatseli TE; Papagoras C; Voulgari PV; Alamanos Y; Drosos AA
Semin Arthritis Rheum; 2011 Apr; 40(5):398-406. PubMed ID: 20843542
[TBL] [Abstract][Full Text] [Related]
28. [Spondylarthropathies and anti-TNFalpha drugs].
Pavy S; Allanore Y; Kahan A
Rev Med Interne; 2005 Sep; 26(9):717-24. PubMed ID: 16154026
[TBL] [Abstract][Full Text] [Related]
29. [The off-label-prescription of TNF-alpha blocking agents for spondyloarthropathies in the context of recent statement by a German federal court].
Sieper J
Z Rheumatol; 2002 Dec; 61(6):688-93. PubMed ID: 12491132
[TBL] [Abstract][Full Text] [Related]
30. [Active WHO class IV lupus nephritis in a patient treated with etanercept for a psoriasic arthritis].
Sacquépée M; Rouleau V; Cantin JF; Quirin N; Doussy Y; Valéry JC; Picu C; Tivollier JM
Nephrol Ther; 2010 Nov; 6(6):537-40. PubMed ID: 20599469
[TBL] [Abstract][Full Text] [Related]
31. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial.
Sterry W; Ortonne JP; Kirkham B; Brocq O; Robertson D; Pedersen RD; Estojak J; Molta CT; Freundlich B
BMJ; 2010 Feb; 340():c147. PubMed ID: 20124563
[TBL] [Abstract][Full Text] [Related]
32. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy.
Lozeron P; Denier C; Lacroix C; Adams D
Arch Neurol; 2009 Apr; 66(4):490-7. PubMed ID: 19364934
[TBL] [Abstract][Full Text] [Related]
33. Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? observational report on six patients: occurrence of uveitis following etanercept treatment.
Kakkassery V; Mergler S; Pleyer U
Curr Eye Res; 2010 Aug; 35(8):751-6. PubMed ID: 20673052
[TBL] [Abstract][Full Text] [Related]
34. Educational session as a tool to increase patient satisfaction of switching etanercept from the prefilled syringe to the autoinjection pen.
Borrás-Blasco J; Gracia-Pérez A; Casterá MD; Rosique-Robles JD; Abad J
Expert Opin Biol Ther; 2013 Aug; 13(8):1103-8. PubMed ID: 23675687
[TBL] [Abstract][Full Text] [Related]
35. Transient and slight thrombocytopaenia induced by etanercept during treatment of psoriatic arthritis.
Stinco G; Piccirillo F; Patrone P
Acta Derm Venereol; 2008; 88(3):281-2. PubMed ID: 18480934
[No Abstract] [Full Text] [Related]
36. [Development of systemic lupus erythematosus with focal proliferative lupus nephritis during anti-TNF-alpha therapy for psoriatic arthritis].
Haake H; Köneke J; Amann K; vom Dahl J; Janssen U
Med Klin (Munich); 2007 Oct; 102(10):852-7. PubMed ID: 17928969
[TBL] [Abstract][Full Text] [Related]
37. Matching-adjusted indirect comparison of adalimumab vs etanercept and infliximab for the treatment of psoriatic arthritis.
Kirson NY; Rao S; Birnbaum HG; Kantor E; Wei RS; Cifaldi M
J Med Econ; 2013; 16(4):479-89. PubMed ID: 23339434
[TBL] [Abstract][Full Text] [Related]
38. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
Barra L; Pope JE; Payne M
J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
[TBL] [Abstract][Full Text] [Related]
39. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients.
Gerloni V; Pontikaki I; Gattinara M; Fantini F
Ann Rheum Dis; 2008 Aug; 67(8):1145-52. PubMed ID: 17981916
[TBL] [Abstract][Full Text] [Related]
40. Etanercept: new preparation. Useful after methotrexate failure in inflammatory rheumatism.
Prescrire Int; 2003 Aug; 12(66):127-32. PubMed ID: 12906020
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
